三联疗法治疗哮喘-慢阻肺重叠的临床疗效观察

Clinical observation of triple therapy in the treatment of asthma COPD overlap

目的观察布地奈德福莫特罗粉吸入剂联合孟鲁司特钠片和卡介菌多糖核酸注射液三联法治疗哮喘-慢阻肺重叠(ACO)患者中临床疗效。方法选择2018年3月到2020年3月收治的120例ACO病例,依据方法的不同,分为对照组、观察组、三联组3组(各40例),对照组使用布地奈德福莫特罗粉吸入剂,观察组使用布地奈德福莫特罗粉吸入剂联合孟鲁司特钠口服片,三联组布地奈德福莫特罗粉吸入剂联合孟鲁司特钠口服片及卡介菌多糖核酸注射液,对其最终的临床疗效观察并比较。结果与观察组、对照组相比,治疗后三联组哮喘控制测试和慢性阻塞性肺病评估测试评分更好(P<0.01);各项肺功能指标更高(P<0.05)。结论布地奈德福莫特罗粉吸入剂联合孟鲁司特钠及卡介菌多糖核酸三联治疗ACO能够得到更为满意的临床疗效。

Objective To observe the clinical efficacy of budesonide and formoterol powder inhalation combined with montelukast sodium tablets and BCG polysaccharide nucleic acid injection in the treatment of asthma COPD(ACO)patients.Methods One hundred and twenty cases of ACO from March 2018 to March 2020 were selected and divided into control group,observation group and triple group(40 cases in each group).The control group used budesonide formoterol powder inhalation,the observation group used budesonide formoterol powder inhalation combined with montelukast sodium oral tablets,and the triple group with budesonide formoterol powder inhalation combined with montelukast sodium oral tablets Taking tablets and BCG polysaccharide nucleic acid injection.The final clinical efficacy was observed and compared.Results Compared with the observation group and the control group,ACT and CAT in the triple therapy group were better(P<0.01),and the lung function indexes were higher(P<0.05).Conclusion Budesonide and formoterol powder inhalation combined with montelukast sodium and BCG polysaccharide nucleic acid triple therapy can obtain more satisfactory clinical efficacy.